Pharmacological inhibition of the CoQ-FSP1 axis re-sensitizes KEAP1-deficient lung cancer tumors, which are inherently resistant to radiotherapy, in part, by inducing ferroptosis. Here, AIFM2 is linked to lung carcinoma.